Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

This 5-year surveillance study assessed the tolerability and safety of acar bose in patients with diabetes. A total of 2035 patients were enrolled of w hom 1954 were classified as having Type 2 diabetes. The study was open with no control group. Physicians had sole control of the acarbose doses prescr ibed. Fasting blood glucose levels, 2-h postprandial glucose levels, HbA(1) or HbA(1C) and other clinical parameters, such as lipids and liver enzyme levels, were also assessed as measures of efficacy and safety. One-third of the patients received acarbose as monotherapy and two-thirds in combinatio n with other glucose-lowering treatment. The concomitant diseases were also assessed. Doses of acarbose were low in the majority of the patients and w ell tolerated. The incidence of acarbose-associated side effects was 4.7%. No sustained adverse changes in laboratory measures occurred. Over the 5 ye ars, HbA(1) and glycated haemoglobin (HbA(1C)) decreased by 2.4 and 1.8% po ints, respectively, and the mean fasting glucose and 2-h postprandial gluco se decreased by 2.7 and 3.3 mmol/l. Mean body weight was reduced by 0.9 kg. The results suggest that when used in long-term day-to-day management of d iabetes, acarbose is well tolerated and can improve glycaemic control as mo notherapy, as well as in combination therapy. In a high-risk patient group acarbose proved to be a safe drug. (C) 2001 Elsevier Science Ireland Ltd. A ll rights reserved.